Viking Therapeutics, Inc. - Common Stock (VKTX)

The financial landscape shifted violently this week as the long-dormant Russell 2000 index (INDEXRUSSELL:RUT) staged a breathtaking 18% rally, marking its best single-week performance in decades. Triggered by a surprisingly soft Consumer Price Index (CPI) report released on Wednesday, the surge has ignited what analysts are calling "The Great

In a decisive shift for equity markets, the small-cap heavy Russell 2000 index outperformed its large-cap peers on Friday, February 13, 2026, as investors cheered a cooler-than-expected Consumer Price Index (CPI) report. The surge reflects a growing market consensus that the Federal Reserve may accelerate its rate-cutting cycle, providing much-needed

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.

Viking (VKTX) Q4 2025 Earnings Call Transcript

The company shared optimistic timelines for advancing the clinical studies of both oral and subcutaneous VK2735 in obesity.

This stock has been known to soar after good news.

Could these two companies be biotech giants in the making?

The stock has climbed in the triple digits over the past three years.

The most recent gold rush in weight loss drugs isn't done just yet.

Eli Lilly and Company (NYSE: LLY) has officially entered the "trillion-dollar club" with a roar, issuing a blockbuster financial guidance for 2026 that projects revenue between $80 billion and $83 billion. The announcement, made during the company’s early February earnings call, marks a historic turning point in the pharmaceutical

In a dramatic week for the pharmaceutical sector, a stark rift has opened between the two undisputed titans of the weight-loss drug market. On February 4, 2026, Eli Lilly (NYSE:LLY) reported a staggering 45% surge in full-year 2025 revenue, propelled by the insatiable global demand for its blockbuster treatments,

This pre-revenue biopharmaceutical stock is a home run swing worth taking.

They could perhaps see sustained runs beyond this year.

Both companies may succeed in this industry.

It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments.

Both could reward patient investors down the line.

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of early 2026, the San Diego-based biotech has transitioned from a promising "dark horse" into a formidable contender challenging the global duopoly of Eli Lilly (NYSE: [...]

This biotech has candidates in late-stage clinical development.

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally underscores the company's status as the undisputed titan of the large-cap healthcare sector, a position bolstered by

These stocks have struggled over the past year but may possess plenty of upside in the future.

Can it become the next biotech leader?